EU court AG concludes in borderline case – “intended use by nature”?
The Advocate General of the EU Court presented his conclusion today in one of the three medical devices borderline cases currently pending at the EU Court, C-219/11 Brain Products vs BioSemi. The other two are C-109/12 Lycocentre and C-308/11 Chemische Fabrik Kreussler, with respect to the latter see also here. The other two are more interesting as far as I am concerned as they address the demarcation vis-a-vis directive 2001/83, the medicinal products directive, and an interesting question about the possi [...] « Read the rest of this article on
medicaldeviceslegal »
